ConductScience.org, home

Paper3301149

The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.

Ferner RE and 1 other. Clin Pharmacokinet, 1987. Cited by 79 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Papers, record 3301149. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3301149

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
The relationship between the pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs.
PubMed
Journal
Clin Pharmacokinet
PubMed
Year
1987
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
79
iCite
Relative citation ratio, by iCite
3.68
iCite
Revised in PubMed
2026-10-11
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Ferner RER E
2Chaplin SS

Source PubMed

Topics4

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Hypoglycemic AgentsMajor topic
Administration, Oral
Humans
Kinetics

Source PubMed

References138

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
17,046,753Effects of tolbutamide on insulin binding to isolated fat cells of the rat.Biochem Pharmacol1982https://conductscience.org/library/papers/7046753PubMed
26,376,219Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal.Diabetes1984https://conductscience.org/library/papers/6376219PubMed
36,759,246Effect of sulfonylurea treatment on in vivo insulin secretion and action in patients with non-insulin-dependent diabetes mellitus.Diabetes1982https://conductscience.org/library/papers/6759246PubMed
46,811,355Pharmacokinetics of intravenous glibenclamide investigated by a high performance liquid chromatographic assay.Diabetologia1982https://conductscience.org/library/papers/6811355PubMed
57,175,719Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results.J Pharm Sci1982https://conductscience.org/library/papers/7175719PubMed
63,517,646Type II diabetes: insulin versus oral agents.N Engl J Med1986https://conductscience.org/library/papers/3517646PubMed
73,923,454Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.Pharmacotherapy1985https://conductscience.org/library/papers/3923454PubMed
87,116,738Bioavailability, pharmacokinetics and effects of glipizide in type 2 diabetics.Clin Pharmacokinet1982https://conductscience.org/library/papers/7116738PubMed
9134,717Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents administered i.v.Arzneimittelforschung1976https://conductscience.org/library/papers/134717PubMed
106,421,561[Pharmacodynamics and pharmacokinetics of 2 glibenclamide preparations in type 2 diabetes. Intraindividual double-blind comparison of Euglucon 5 (HB 419) and Euglucon N (HB 420)].Dtsch Med Wochenschr1984https://conductscience.org/library/papers/6421561PubMed
11690,998Metabolic fate of tolazamide in man and in the rat.J Med Chem1978https://conductscience.org/library/papers/690998PubMed
124,704,717Effect of chlorpropamide treatment on insulin secretion in diabetics: its relationship to the hypoglycemic effect.Metabolism1973https://conductscience.org/library/papers/4704717PubMed
13913,025Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole.Clin Pharmacol Ther1977https://conductscience.org/library/papers/913025PubMed
1414,318,586FAILURE OF PROLONGED SULFONYLUREA ADMINISTRATION TO ENHANCE INSULOGENIC RESPONSE TO GLYCEMIC STIMULUS.Diabetes1965https://conductscience.org/library/papers/14318586PubMed
154,032,245Effect of food and tablet age on relative bioavailability and pharmacodynamics of two tolbutamide products.J Pharm Sci1985https://conductscience.org/library/papers/4032245PubMed
163,089,912Massive glibenclamide overdose without hypoglycaemia in a man with diabetes after partial pancreatectomy.Hum Toxicol1986https://conductscience.org/library/papers/3089912PubMed
17389,600Glipizide: a review of its pharmacological properties and therapeutic use.Drugs1979https://conductscience.org/library/papers/389600PubMed
183,935,463Absorption of glibenclamide from different sites of the gastro-intestinal tract.Eur J Clin Pharmacol1985https://conductscience.org/library/papers/3935463PubMed
197,028,776Differential effects of tolbutamide on first and second phase insulin secretion in noninsulin-dependent diabetes mellitus.J Clin Endocrinol Metab1981https://conductscience.org/library/papers/7028776PubMed
20569,611Pharmacogenetics of tolbutamide metabolism in humans.Diabetes1979https://conductscience.org/library/papers/569611PubMed

See all 138 references

Cited by21

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 79 citations.

PMIDTitleJournalYearIn PapersSource
26,551,662Treatment of sulfonylurea and insulin overdose.Br J Clin Pharmacol2016https://conductscience.org/library/papers/26551662PubMed
23,440,669Interactions of rosiglitazone and anti-arrhythmic drugs in animal model.Ann Med Health Sci Res2012https://conductscience.org/library/papers/23440669PubMed
21,264,118Drug-drug Interaction between Pravastatin and Gemfibrozil (Antihyperlipidemic) with Gliclazide (Antidiabetic) in Rats.J Young Pharm2010https://conductscience.org/library/papers/21264118PubMed
20,437,462Contributions of human cytochrome P450 enzymes to glyburide metabolism.Biopharm Drug Dispos2010https://conductscience.org/library/papers/20437462PubMed
16,372,821Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance.Clin Pharmacokinet2005https://conductscience.org/library/papers/16372821PubMed
16,356,235Bench-to-bedside review: Antidotal treatment of sulfonylurea-induced hypoglycaemia with octreotide.Crit Care2005https://conductscience.org/library/papers/16356235PubMed
9,825,953Management of antidiabetic medications in overdose.Drug Saf1998https://conductscience.org/library/papers/9825953PubMed
8,972,242Oral antidiabetic drug use in the elderly.Drugs Aging1996https://conductscience.org/library/papers/8972242PubMed
8,853,933Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.Clin Pharmacokinet1996https://conductscience.org/library/papers/8853933PubMed
8,739,909Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?Diabetologia1996https://conductscience.org/library/papers/8739909PubMed
8,312,676Problems and pitfalls of sulphonylurea therapy in older patients.Drugs Aging1993https://conductscience.org/library/papers/8312676PubMed
7,988,624The effect of hyperglycaemia on the absorption of glibenclamide in patients with non-insulin-dependent diabetes mellitus.Eur J Clin Pharmacol1994https://conductscience.org/library/papers/7988624PubMed
7,848,543Comparative tolerability profiles of oral antidiabetic agents.Drug Saf1994https://conductscience.org/library/papers/7848543PubMed
7,741,982Antihyperglycaemic agents. Drug interactions of clinical importance.Drug Saf1995https://conductscience.org/library/papers/7741982PubMed
3,129,103Sulphonylureas and hypoglycaemia.Br Med J (Clin Res Ed)1988https://conductscience.org/library/papers/3129103PubMed
2,656,043Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.Clin Pharmacokinet1989https://conductscience.org/library/papers/2656043PubMed
2,651,086Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.Drugs1989https://conductscience.org/library/papers/2651086PubMed
2,271,372The effect of cholestyramine and activated charcoal on glipizide absorption.Br J Clin Pharmacol1990https://conductscience.org/library/papers/2271372PubMed
2,116,159Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus.Br J Clin Pharmacol1990https://conductscience.org/library/papers/2116159PubMed
2,109,700Possible protein binding displacement interaction between glibenclamide and metolazone.Eur J Clin Pharmacol1990https://conductscience.org/library/papers/2109700PubMed

See all 21 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3301149

GET https://conductscience.org/api/papers/v1/3301149/references?page=2